Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

By Y. Goekoop-Ruiterman, J. Vries-Bouwstra, C. Allaart, D. Zeben, P. Kerstens, J. Hazes, A. Zwinderman, H. Ronday, K. Han, M. Westedt and 6 more. Arthritis & Rheumatism, 2005

1,552 citations recorded by the source corpus.

Subfields: Rehabilitation, Rheumatology

View Paper: https://www.semanticscholar.org/paper/2e9f4f640a7223030b79549fe2ae19a4e1a79b01

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. Daniel Aletaha
2. I. McInnes
3. Georg Schett
4. J. Smolen
5. S. Gaffen
6. Gary S. Firestein

Citations in the corpus

• Cytokines in the pathogenesis of rheumatoid arthritis (2007, background): “General suppression of inflammation at early stages of disease may offer a similar potential, such as through TNF blockad”
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, positive): “49 75–77 The SLR on this allowed a fi rm conclusion to be drawn.”
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, positive): “This pertains to bsDMARDs, for which the Task Force relies on the stringency of the regulatory processes of EMA and FDA, for new IL-6 inhibitors and for Jak-inhibitors, the fi rst of which was only licensed in some parts of the world at the time of developing these recommendations, with increasing…”